Deal is part of $245 million package announced last year Novartis, Endo unit accused of conspiring to keep competitors out Feb 23 (Reuters) - Swiss drugmaker Novartis AG has agreed to pay $30 million ...
Novartis AG has agreed to pay $245 million to end antitrust litigation accusing the company of trying to delay the launch of generic versions of the drug Exforge in the United States, according to a ...
NEW YORK, Dec 28 (Reuters) - Novartis AG (NOVN.S), opens new tab said on Wednesday it will pay $245 million to end antitrust litigation accusing the Swiss drugmaker of trying to delay the launch in ...
Novartis has decided to end a classic generic pay-for-delay legal battle with a series of settlements. The Swiss pharma will pay altogether $245 million in separate settlements with direct purchasers, ...
(Reuters) - Swiss drugmaker Novartis AG has agreed to pay $30 million to settle claims by health plans and consumers that it schemed to delay the U.S. launch of generic competition for its Exforge ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results